itraconazole + voriconazole

Itraconazole + voriconazole is a combination of two triazole antifungal agents, both of which inhibit fungal ergosterol synthesis by targeting the enzyme lanosterol 14α-demethylase. This combination has been studied in vitro for potential synergistic effects against certain fungal pathogens, such as Fusarium species, with some evidence suggesting synergism in about 50% of tested strains[1]. Both drugs are used individually to treat serious systemic fungal infections including invasive aspergillosis and candidemia. The use of this combination is not standard clinical practice due to overlapping mechanisms, potential for drug-drug interactions, and increased risk of adverse events; it may be considered only under special circumstances or within research settings[2][1]. Itraconazole and voriconazole are metabolized by hepatic cytochrome P450 enzymes and can interact with many other medications[5][7].